Peptoids: The Indestructible Cousins of Peptides That Could Become Next-Generation Drugs
Peptoids are synthetic peptide-like molecules that are completely immune to the enzymes that destroy natural peptides, making them promising candidates for drugs in areas from infection to cancer.
Quick Facts
What This Study Found
Peptoids are synthetic molecules with a peptide-like backbone but with side chains attached to nitrogen instead of carbon, making them completely resistant to protease degradation — the main reason natural peptides break down so quickly in the body. Sequences up to 50 units long can be synthesized with precise control over composition and diverse side chain chemistry.
The review covers therapeutic applications across four areas: lung surfactant replacement therapy, antimicrobial agents, cancer therapeutics, and diagnostics. Peptoids have demonstrated bioactivity both as protein mimics and as replacements for small molecule drugs, with particular promise in lipid-associated applications where their protease resistance gives them a major advantage over natural peptides.
Key Numbers
up to 50 units in length · complete protease resistance · invented early 1990s · N-substituted glycine backbone
How They Did This
Comprehensive review of peptoid research advances covering synthesis methods, structural characterization, and therapeutic applications in lung surfactant therapy, antimicrobial agents, cancer, and diagnostics, with emphasis on in vitro and in vivo studies.
Why This Research Matters
The biggest problem with peptide drugs is that the body destroys them within minutes. Peptoids solve this fundamental limitation by subtly rearranging the molecular structure to make it invisible to proteases while retaining peptide-like biological activity. If peptoids can replicate peptide functions with dramatically improved stability, they could unlock therapeutic applications that peptides alone cannot achieve.
The Bigger Picture
Peptoids represent one of several peptidomimetic strategies competing to solve the peptide stability problem. While other approaches like D-amino acids, cyclic peptides, and stapled peptides each offer partial solutions, peptoids' complete protease resistance is unique. If the structural design challenges can be overcome, peptoids could fill the gap between small molecule drugs (stable but limited targets) and peptide/protein biologics (versatile but fragile).
What This Study Doesn't Tell Us
As a review, this synthesizes existing research without new experimental data. While peptoids show promise in multiple therapeutic areas, most applications remain preclinical. The structural landscape of peptoids is less well-defined than that of peptides, making rational design more challenging. The relationship between peptoid structure and biological function is still being elucidated.
Questions This Raises
- ?Which therapeutic application is closest to clinical trials for peptoid-based drugs?
- ?How does the reduced structural predictability of peptoids compared to peptides affect rational drug design?
- ?Can peptoids achieve oral bioavailability, or do they still face absorption challenges despite protease resistance?
Trust & Context
- Key Stat:
- 100% protease-resistant Peptoids are completely resistant to protease degradation — the main reason natural peptides fail as drugs — due to their N-substituted glycine backbone
- Evidence Grade:
- This is a comprehensive review in Current Pharmaceutical Design covering peptoid synthesis, structure, and therapeutic applications. While it provides a thorough overview, most applications discussed are preclinical, and the field's maturity is moderate.
- Study Age:
- Published in 2011 in Current Pharmaceutical Design. Peptoid research has advanced significantly since publication — newer reviews may cover more recent clinical progress. However, the fundamental chemistry and design principles described remain valid.
- Original Title:
- Peptoids: bio-inspired polymers as potential pharmaceuticals.
- Published In:
- Current pharmaceutical design, 17(25), 2732-47 (2011)
- Authors:
- Dohm, Michelle T, Kapoor, Rinki, Barron, Annelise E(2)
- Database ID:
- RPEP-01755
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What's the difference between a peptide and a peptoid?
Both have a similar backbone structure, but in peptides the side chains attach to the alpha carbon, while in peptoids they attach to the nitrogen. This seemingly small change makes peptoids completely invisible to proteases — the enzymes that rapidly destroy natural peptides in the body.
Why aren't peptoid drugs available yet if they're so stable?
While protease resistance solves one major problem, designing peptoids with the right shape and biological activity is more challenging than with peptides. Peptoid structures are less predictable, making it harder to engineer specific functions. The field is advancing but still working through these design challenges before reaching clinical trials.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01755APA
Dohm, Michelle T; Kapoor, Rinki; Barron, Annelise E. (2011). Peptoids: bio-inspired polymers as potential pharmaceuticals.. Current pharmaceutical design, 17(25), 2732-47.
MLA
Dohm, Michelle T, et al. "Peptoids: bio-inspired polymers as potential pharmaceuticals.." Current pharmaceutical design, 2011.
RethinkPeptides
RethinkPeptides Research Database. "Peptoids: bio-inspired polymers as potential pharmaceuticals..." RPEP-01755. Retrieved from https://rethinkpeptides.com/research/dohm-2011-peptoids-bioinspired-polymers-as
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.